Atara Biotherapeutics
Allogeneic EBV-specific T-cell therapy (tab-cel) targeting post-transplant lymphoproliferative disorder
- Sector
- Biotech
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 3
- 14 pending · first 2024
- Rank in peer group#339 of 1449
Capital timeline
No federal awards or Form D filings are on record for this company.
Many early companies raise without filing a Form D, or have not yet won a federal award. New records appear here as the sources update.
Checked: SEC EDGAR Form D through Oct 23, 2026; SBIR and STTR awards through Oct 21, 2026; USAspending contract awards
Founder? Add funding contextStanding among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#339 · top 23%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 3 granted of 17- GrantedAntigen Specific CD19-TARGETED Car-t CellsUSPTOUS 12,617,849
- GrantedAdministration Of An Anti-activin-a Compound To A SubjectUSPTOUS 12,383,572
- PendingSystems And Methods For Distributing Cell TherapiesUSPTOApplication 19006853
Show all 17 patent records
- Antigen Specific CD19-TARGETED Car-t CellsMay 5, 2026 · US 12,617,849Granted
- Administration Of An Anti-activin-a Compound To A SubjectAug 12, 2025 · US 12,383,572Granted
- Systems And Methods For Distributing Cell TherapiesJul 10, 2025 · Application 19006853Pending
- Methods Of Managing Tumor Flare In Adoptive ImmunotherapyMar 12, 2024 · US 11,925,663Granted
- Car T Cells That Target Aspergillus-associated AntigensJan 12, 2023 · Application 17783469Pending
- Methods For Expanding Antigen-specific Car-t Cells, Compositions And Uses Related TheretoSep 30, 2021 · Application 17274673Pending
- Systems And Methods For Distributing Cell TherapiesNov 5, 2020 · Application 16960767Pending
- Methods For Expanding Antigen-specific Car-t Cells, Compositions And Uses Related TheretoApplication PCTUS2019050404Pending
- Systems And Methods For Distrubuting Cell TherapiesApplication PCTUS2019012542Pending
- Methods Of Managing Tumor Flare In Adoptive ImmunotherapyApplication PCTUS2018056824Pending
- Bispecific CD19/CD20-TARGETED Chimeric Antigen Receptors And Uses ThereofApplication 19524605Pending
- Bispecific CD19/CD20-TARGETED Chimeric Antigen Receptors And Uses ThereofApplication PCTUS2024049668Pending
- GPC3-TARGETED Molecules And Uses ThereofApplication PCTUS2024035468Pending
- Bispecific CD19/CD20-TARGETED Chimeric Antigen Receptors And Uses ThereofApplication 63587646Pending
- Car T Cells That Target Aspergillus Associated AntigensApplication PCTUS2020063582Pending
- CLEC4-TARGETED Car-t-cellsApplication PCTUS2020032003Pending
- Antigen Specific CD19-TARGETED Car-t CellsApplication PCTUS2020030435Pending
Related companies, and why
- AdvanCellSimilar federal contract value in Biotech · null in contracts
- TARN BIOSCIENCES, INC.Similar federal contract value in Biotech · null in contracts
- ADVANCED PROCESS COMBINATORICS, INC.Similar federal contract value in Biotech · null in contracts
- IMMUNEXT, INC.Similar federal contract value in Biotech · null in contracts
- NOVORON BIOSCIENCE INCSimilar federal contract value in Biotech · null in contracts
- ADAPTIN BIO, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .